Overview

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

Status:
Terminated

Trial end date:
2017-10-02

Target enrollment:

Participant gender:

Summary

This trial is to assess the safety & efficacy of the Combination of Pembrolizumab and Lenalidomide in the management of patients with Relapsed Hodgkin Lymphoma.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lenalidomide
Pembrolizumab
Thalidomide